A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Summary

This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.

Timeline

Start

2026-01-28

Primary completion

2027-12

Completion

2027-12

Drugs

Indications